BIO, PhRMA and US Chamber of Commerce express fear of UN High-Level Panel on Access to Medicines in letter to Senator Hatch

Posted on by Thiru

In a sternly worded letter dated 18 February 2016, the Biotechnology Innovation Organization (BIO), the National Association of Manufacturers (NAM), the National Foreign Trade Council (NFTC), the Pharmaceutical Research and Manufacturers of America (PhRMA), the U.S. Chamber of Commerce (the Chamber) and the United States Council for International Business (USCIB) wrote Senator Orrin Hatch (Republican – Utah) expressing serious reservations with the United Nations High-Level Panel on Access to Medicines (UN HLP). Continue Reading →

11 Groups Urge NIH to Lower Price of Xtandi, NIH/Army-Funded Prostate Cancer Drug With $129k/Year Price Tag

Posted on by Zack Struver

CONTACT:
Zack Struver
zack.struver@keionline.org
+1 (914) 582-1428

FOR RELEASE: MARCH 21, 2016

Non-Profit Groups Urge Obama Administration, NIH to Lower Price of Government-Funded, $129,000 Per Year Prostate Cancer Drug
The groups asked the National Institutes of Health to “take this opportunity to act” to lower the price of the prostate cancer drug Xtandi and show leadership on deterring discriminatory pricing practices.

Continue Reading →

Uncategorized

Briefing on Beijing Treaty on Audiovisual Performers

Posted on by Manon Ress

On Monday, March 7, 2016, from 1:45 P.M. to 2:45 P.M., the US Patent and Trademark Office (USPTO) met with invited stakeholders in a briefing at the White House on the Beijing Treaty on Audiovisual Performances and the implementation package that was sent to Congress on February 29, 2016. The package was submitted for review to the Senate Foreign Relations and Judiciary Committees.

Continue Reading →

Uncategorized